RobertHarringtonMD
Cardiology • New York, NYInterventional Cardiology
Stephen and Suzanne Weiss Dean, Weill Cornell Medicine and Provost for Medical Affairs, Cornell University
Dr. Harrington is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Office of the Dean
1300 York Avenue, F-113
New York, NY 10065Phone+1 212-746-6005
Education & Training
Duke University HospitalFellowship, Cardiovascular Disease, 1990 - 1993
UMass Chan Medical SchoolResidency, Internal Medicine, 1986 - 1989
Tufts University School of MedicineClass of 1986
Certifications & Licensure
CA State Medical License 2012 - 2025
NY State Medical License 2023 - 2025
NC State Medical License 1993 - 2017
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACC) American College of Cardiology
Clinical Trials
- A Clinical Trial to Demonstrate the Efficacy of Cangrelor Start of enrollment: 2006 Apr 01
- Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. Start of enrollment: 2006 Sep 01
- A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome Start of enrollment: 2006 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Oral Factor XIa Inhibitor Milvexian After a Recent Acute Coronary Syndrome: Rationale and Design of the Phase 3 (Librexia ACS).C Michael Gibson, M Cecilia Bahit, Roxana Mehran, Shamir R Mehta, Rasha Al Lamee
American Heart Journal. 2025-02-20 - Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome.Gregory G Schwartz, Michael Szarek, Esther Reijnders, J Wouter Jukema, Deepak L Bhatt
European Journal of Preventive Cardiology. 2025-02-08 - Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial.Gregory G Schwartz, Michael Szarek, J Wouter Jukema, Christa M Cobbaert, Esther Reijnders
Diabetes Care. 2025-02-06
Journal Articles
- Alirocumab and Cardiovascular Outcomes After Acute Coronary SyndromeVera A Bittner, Kenneth W Mahaffey, Deepak L Bhatt, Robert A Harrington, Gregory G Schwartz, Matthew T Roe, The New England Journal of Medicine
- Impact of Lesion Complexity on Peri-Procedural Adverse Events and the Benefit of Potent Intravenous Platelet Adenosine Diphosphate Receptor Inhibition After Percutaneo...Gregg W Stone, Matthew J Price, Philippe Genereux, C Michael Gibson, Deepak L Bhatt, Robert A Harrington, Kenneth W Mahaffey, European Heart Journal
- Effects of Genetic Variation in Protease Activated Receptor 4 After an Acute Coronary Syndrome: Analysis from the TRACER TrialPaolo Fortina, David J Moliterno, Robert A Harrington, Kenneth W Mahaffey, ScienceDirect
Press Mentions
Dr. Samara Reck-Peterson Named Chair of the Department of Biochemistry and Biophysics at Weill Cornell MedicineJanuary 31st, 2025- This Week in CardiologyJanuary 31st, 2025
- This Week in CardiologyJanuary 24th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
